Evogene Ltd. Reports Q3 2025 Financial Results

Ticker: EVGN · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1574565

Sentiment: neutral

Topics: earnings, financial-results, sec-filing

TL;DR

Evogene dropped its Q3 2025 earnings report on 11/20/25.

AI Summary

Evogene Ltd. announced its financial results for the third quarter ended September 30, 2025, on November 20, 2025. The company filed a Form 6-K report with the SEC, which includes the press release detailing these results as Exhibit 99.1.

Why It Matters

This filing provides investors with an update on Evogene's financial performance for the third quarter of 2025, allowing them to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial results filing and does not contain significant new risk factors.

Key Players & Entities

FAQ

What period do the financial results in this filing cover?

The financial results cover the third quarter ended September 30, 2025.

When did Evogene Ltd. announce these financial results?

Evogene Ltd. announced its financial results on November 20, 2025.

What form is this SEC filing?

This is a Form 6-K report.

What is included as an exhibit to this Form 6-K?

A press release announcing the financial results for the third quarter ended September 30, 2025, is furnished as Exhibit 99.1.

Does Evogene Ltd. file annual reports under Form 20-F or 40-F?

Evogene Ltd. files annual reports under Form 20-F.

Filing Stats: 375 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-11-20 07:00:22

Filing Documents

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS On November 20, 2025, Evogene Ltd. (" Evogene ") announced its financial results for the third quarter ended September 30, 2025. A Copy of the press release announcing those results is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") and is incorporated herein by reference. Evogene is holding a conference call on November 20, 2025 to discuss its quarterly results for the quarter ended September 30, 2025 and, in connection with that call, will make available to its investors a slide presentation to provide additional information regarding its business and its financial results. That slide presentation is attached as Exhibit 99.2 to this Form 6-K and is incorporated herein by reference. The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (" SEC ") File No. 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443, 333-203856, 333-286197 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 20, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release: Evogene Reports Third Quarter 2025 Financial Results. 99.2 Slide presentation for conference call of Evogene held on November 20, 2025, discussing Evogene's quarterly financial results for the third quarter of 2025.

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing